Related Experiment Video
Updated: Nov 1, 2025
Complete and Partial Resuscitative Endovascular Balloon Occlusion of the Aorta for Hemorrhagic Shock
Published on: May 19, 2022
Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants
Antonio Gómez-Outes1, Pau Alcubilla2, Gonzalo Calvo-Rojas3
1Division of Pharmacology and Clinical Drug Evaluation, Spanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain.
Insights
Direct oral anticoagulant reversal agents show effective hemostasis but high mortality persists. Failure to achieve hemostasis significantly increases death risk, necessitating further research into optimal reversal strategies.
Area of Science:
- Cardiology
- Pharmacology
- Hematology
Background:
- Direct oral anticoagulants (DOACs) offer a favorable benefit-risk profile but carry a risk of major bleeding (2-3.5% annually).
- Severe DOAC-associated bleeding often necessitates hospitalization and the use of reversal agents to control hemorrhage.
Purpose of the Study:
- To evaluate clinical outcomes of using 4-factor prothrombin complex concentrates, idarucizumab, or andexanet for reversing severe DOAC-associated bleeding.
- To compare mortality rates, thromboembolic events, and hemostatic efficacy across different reversal agents.
Main Methods:
- Systematic literature search for studies on DOAC reversal agents in severe bleeding.
- Meta-analysis of mortality, thromboembolic events, and hemostatic efficacy using a random effects model.
- Evaluation of 60 studies involving 4,735 patients treated with 4-factor PCC, idarucizumab, or andexanet.
Main Results:
- Overall mortality rate was 17.7%, higher in intracranial (20.2%) versus extracranial (15.4%) bleeding.
- Thromboembolism rate was 4.6%, notably high with andexanet (10.7%).
- Effective hemostasis rate was 78.5%, consistent across agents; failure to achieve hemostasis strongly correlated with mortality (RR 3.63).
Conclusions:
- Despite high effective hemostasis rates with reversal agents, the risk of death from severe DOAC-related bleeding remains significant.
- Failure to achieve effective hemostasis is a critical predictor of fatal outcomes.
- High thromboembolism rates with andexanet and the persistent risk of death underscore the need for comparative clinical trials.
Background:
Direct oral anticoagulants (DOACs) have shown a positive benefit-risk balance in both clinical trials and real-world data, but approximately 2% to 3.5% of patients experience major bleeding annually. Many of these patients require hospitalization, and the administration of reversal agents may be required to control bleeding.
Objectives:
The aim of this study was to investigate clinical outcomes associated with the use of 4-factor prothrombin complex concentrates, idarucizumab, or andexanet for reversal of severe DOAC-associated bleeding.
Methods:
The investigators systematically searched for studies of reversal agents for the treatment of severe bleeding associated with DOAC. Mortality rates, thromboembolic events, and hemostatic efficacy were meta-analyzed using a random effects model.
Results:
The investigators evaluated 60 studies in 4,735 patients with severe DOAC-related bleeding who were treated with 4-factor prothrombin complex concentrates (n = 2,688), idarucizumab (n = 1,111), or andexanet (n = 936). The mortality rate was 17.7% (95% confidence interval [CI]: 15.1% to 20.4%), and it was higher in patients with intracranial bleedings (20.2%) than in patients with extracranial hemorrhages (15.4%). The thromboembolism rate was 4.6% (95% CI: 3.3% to 6.0%), being particularly high with andexanet (10.7%; 95% CI: 6.5% to 15.7%). The effective hemostasis rate was 78.5% (95% CI: 75.1% to 81.8%) and was similar regardless of the reversal agent considered. The rebleeding rate was 13.2% (95% CI: 5.5% to 23.1%) and 78% of rebleeds occurred after resumption of anticoagulation. The risk of death was markedly and significantly associated with failure to achieve effective hemostasis (relative risk: 3.63; 95% CI: 2.56 to 5.16). The results were robust regardless of the type of study or the hemostatic scale used.
Conclusions:
The risk of death after severe DOAC-related bleeding remains significant despite a high rate of effective hemostasis with reversal agents. Failure to achieve effective hemostasis strongly correlated with a fatal outcome. Thromboembolism rates are particularly high with andexanet. Comparative clinical trials are needed.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:28Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
01:30Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...